# Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers

> **NCT02251145** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 49 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tipranavir low dose
- **DRUG:** Tipranavir high dose
- **DRUG:** Ritonavir low dose
- **DRUG:** Ritonavir high dose
- **DRUG:** Tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT02251145
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2002-06
- **Final completion:** —
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251145, "Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02251145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*